These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7554473)

  • 21. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe combined immunodeficiency and adenosine deaminase deficiency: failure of enzyme replacement therapy.
    Ziegler JB; Lee CH; Van der Weyden MB; Bagnara AS; Beveridge J
    Arch Dis Child; 1980 Jun; 55(6):452-7. PubMed ID: 7436484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID).
    Chakravarti VS; Borns P; Lobell J; Douglas SD
    Pediatr Radiol; 1991; 21(6):447-8. PubMed ID: 1749685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients.
    Malacarne F; Benicchi T; Notarangelo LD; Mori L; Parolini S; Caimi L; Hershfield M; Notarangelo LD; Imberti L
    Eur J Immunol; 2005 Nov; 35(11):3376-86. PubMed ID: 16276484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cellular and molecular therapy in severe combined immunodeficiencies].
    Porta F; Candotti F; Arrighini A; Lanfranchi A; Ugazio AG
    Pediatr Med Chir; 1991; 13(2):135-8. PubMed ID: 1896378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
    Bory C; Boulieu R; Souillet G; Chantin C; Guibaud P; Hershfield MS
    Adv Exp Med Biol; 1991; 309A():173-6. PubMed ID: 1789201
    [No Abstract]   [Full Text] [Related]  

  • 27. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful lectin-separated bone marrow transplantation in adenosine deaminase deficiency-related severe immunodeficiency.
    Nespoli L; Porta F; Locatelli F; Aversa F; Carotti A; Lanfranchi A; Gibardi A; Marchesi ME; Abate L; Martelli MF
    Haematologica; 1990; 75(6):546-50. PubMed ID: 2098297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.
    Liu P; Santisteban I; Burroughs LM; Ochs HD; Torgerson TR; Hershfield MS; Rawlings DJ; Scharenberg AM
    Clin Immunol; 2009 Feb; 130(2):162-74. PubMed ID: 18952502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
    Booth C; Hershfield M; Notarangelo L; Buckley R; Hoenig M; Mahlaoui N; Cavazzana-Calvo M; Aiuti A; Gaspar HB
    Clin Immunol; 2007 May; 123(2):139-47. PubMed ID: 17300989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.
    Hutton JJ; Wiginton DA; Coleman MS; Fuller SA; Limouze S; Lampkin BC
    J Clin Invest; 1981 Aug; 68(2):413-21. PubMed ID: 7263861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
    Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
    Front Immunol; 2018; 9():113. PubMed ID: 29456531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities.
    Blackburn MR; Aldrich M; Volmer JB; Chen W; Zhong H; Kelly S; Hershfield MS; Datta SK; Kellems RE
    J Biol Chem; 2000 Oct; 275(41):32114-21. PubMed ID: 10908569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y; Ariga T; Ohtsu M
    Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconstitution of T- and B-cell function after T-lymphocyte-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency due to adenosine deaminase deficiency.
    Silber GM; Winkelstein JA; Moen RC; Horowitz SD; Trigg M; Hong R
    Clin Immunol Immunopathol; 1987 Sep; 44(3):317-20. PubMed ID: 3304740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
    Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
    Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
    [No Abstract]   [Full Text] [Related]  

  • 38. Enzyme replacement product approved for rare immunodeficiency disorder.
    Clin Pharm; 1990 Jun; 9(6):408. PubMed ID: 2364646
    [No Abstract]   [Full Text] [Related]  

  • 39. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.
    Serana F; Sottini A; Chiarini M; Zanotti C; Ghidini C; Lanfranchi A; Notarangelo LD; Caimi L; Imberti L
    J Immunol; 2010 Dec; 185(12):7713-22. PubMed ID: 21057082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.